Live Breaking News & Updates on Urologic Oncology Program

Stay updated with breaking news from Urologic oncology program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR /KEYNOTE-581 trial

Final results will be presented at ASCO 2023. | May 25, 2023 ....

New Zealand , United States , Thomas Hutson , Corina Dutcus , Gregory Lubiniecki , Urologic Cancer Research , Merck Co Inc , Eisai Inc , Urologic Oncology Program , Treatment Center , International Metastatic , United Nations Sustainable Development Goals Sdgs , Statement Of Merck Co Inc , American Society Of Clinical Oncology , Merck Research Laboratories , Oncology At Eisai Inc , Eisai Europe Ltd , Global Clinical Development , Database Consortium , Memorial Sloan Kettering Cancer Center , Eisai Co Ltd , Clinical Development , Exchange Commission , Texas Oncology At Baylor Sammons Cancer Center , Clinical Oncology , Annual Meeting ,

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, . ....

United States , New Zealand , Gregory Lubiniecki , Corina Dutcus , Thomas Hutson , Global Clinical Development , International Metastatic , Eisai Co Ltd , Urologic Cancer Research , Database Consortium , Merck Research Laboratories , Eisai Europe Ltd , Treatment Center , Merck Co Inc , Urologic Oncology Program , Statement Of Merck Co Inc , Clinical Development , United Nations Sustainable Development Goals Sdgs , Eisai Inc , Texas Oncology At Baylor Sammons Cancer Center , Exchange Commission , Memorial Sloan Kettering Cancer Center , Oncology At Eisai Inc , Merck Co Stock , Texas Oncology , Baylor Sammons Cancer ,

Nivolumab Maintains DFS Benefit in MIUC and MIBC After Radical Surgery

Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer. ....

United States , Matthew Milowsky , Nivolumab Opdivo , Lineberger Comprehensive Cancer Center , Urologic Oncology Program , American Urological Association Annual Meeting , Urological Association Annual , Comprehensive Cancer Center , American Urological Association Annual Meeting , Muscle Invasive Urothelial Carcinoma , Muscle Invasive Bladder Cancer , Phase 3 Checkmate 274 Trial ,

New nanotechnology-based test can detect and profile prostate cancers even in microscopic amounts

Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers-;even in microscopic amounts. ....

Dan Theodorescu , Edwin Posadas , Emily Henderson , Urologic Oncology Program , Cancer Research , Cancer Research Industry , Experimental Therapeutics Program In Cedars , Sinai Cancer , Experimental Therapeutics Program , Scoring Assay , Research Industry Focus , Cedars Sinai Cancer , Molecular Twin , Prostate Cancer , Radiation Therapy ,

To Combat Opioid Epidemic, Step Up Safe Prescribing Practices, Expert Urges

Overprescribing a continuing problem, Benjamin Davies tells urologists ....

United States , Mike Bassett , Benjamin Davies , Tracey Krupski , Urologic Oncology Program , Society Of Urologic Oncology , University Of Pittsburgh School Medicine , University Of Virginia , American Urological Association , Pittsburgh School , Urologic Oncology , Pittsburgh Medical Center , Hillman Cancer Center ,